Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Neoadjuvant in NSCLC (IDEAR)
NCT05267392Phase 2Unknown
- Sponsor
- Instituto Português de Oncologia do Porto
- Start
- Feb 2021
- Primary completion
- Jul 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Instituto Português de Oncologia do Porto. Primary endpoint: Incidence of Dose-Limiting Toxicity. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05267392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267392.